September 2020—Diaceutics announced two partnerships, with Targos Molecular Pathology and HistoCyte Laboratories, on its DXRX platform, an end-to-end solution for the development and commercialization of precision medicine diagnostics.
As a network partner to DXRX, Targos will provide laboratories with its Targos Advance Expert training and quality assurance support along with comparison studies and ring studies. Targos aims to enable laboratories to benchmark their performance against other laboratories and ensure that patients receive the same quality of testing. HistoCyte will help laboratories to standardize and evaluate the performance of their immunohistochemistry and fluorescence in situ hybridization assays by providing single slide control materials.
Targos and HistoCyte’s services will be available to a select number of laboratories within Diaceutics’ network of more than 2,500 labs. The pilot collaboration will focus on PD-L1 testing.
Diaceutics, +44 28 9072 6123